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Hodgkin’s lymphoma
Christoph Renné1*, Alexander H Benz1,2 and Martin L Hansmann1Abstract
Background: Hodgkin lymphoma (HL) is one of the most frequent lymphoma in the western world. Despite a good
overall prognosis, some patients suffer relapsing tumors which are difficult to cure. Over a long period Vitamin D has
been shown to be a potential treatment for cancer. Vitamin D acts via the vitamin D receptor, a nuclear receptor,
acting as an inducible transcription factor. We aimed to investigate the expression of vitamin D receptor as a possible
diagnostic marker and potential therapeutic target in HL as well as in B-cell derived non-Hodgkin lymphoma (B-NHL).
Methods: We used a panel of 193 formalin fixed tissues of lymphoma cases consisting of 55 cases of HL and 138 cases
on several B-NHL entities.
Results: Vitamin D receptor is strongly expressed in tumor cells of HL, regardless of the sub entity with an overall
positivity of 80% of all HL cases. In contrast, only about 17% of the analyzed origin-NHL showed positivity for vitamin D
receptor. The detection of nuclear localization of vitamin D receptor in the tumor cells of HL suggests activated status
of the vitamin D receptor.
Conclusions: Our study suggests VDR as a specific marker for tumor cells of HL, but not of B-NHL subtypes. Further,
the observed nuclear localization suggests an activated receptor status in tumor cells of HL. Further investigations of
mutational status and functional studies may shed some light in functional relevance of vitamin D receptor signaling in
HL.Background
Hodgkin lymphoma (HL) is one of the most frequent
lymphomas. Most of cases belong to the classical (c)
subtype of HL (cHL), while only few percent of cases
represent nodular lymphocyte predominant HL
(NLPHL) [1]. The group of cHL is further subdivided
into 4 distinct histological subgroups namely into nodu-
lar sclerosis (NS), mixed cellularity (MC), lymphocyte-
depleted and lymphocyte-rich HL. In NLPHL, the tumor
cells the so called lymphocyte predominant cells (LP),
and also the tumor cells of cHL the Hodgkin and Reed-
Sternberg (HRS) cells account for a few percent of
total tumor tissue the maiority of the cellular infiltrate
comprises of T-lymphocytes, histiocytes, eosinophilic
granulocytes and plasma cells [1]. All LP cells and
mostly HRS cells are of B-cell origin [2-4]. Despite the* Correspondence: C.Renne@em.uni-frankfurt.de
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reproduction in any medium, provided the orHRS cells being mostly of B-cell origin they are lacking
mostly of the B-cell expression program [5].
The genetic alterations involved in the pathogenesis of
HL are still largely unknown. HRS cells in most if not all
cases show numerical chromosome aberrations, amplifi-
cations and deletions of chromosomal subregions [6,7].
In addition, genetic alterations that contribute to consti-
tutive NFκB activation in HRS cells have been identified
[8-11]. For a large fraction of cases, infection of HRS-cell
precursors with the Epstein-Barr virus (EBV) and ex-
pression of the viral latent membrane proteins (LMPs) 1
and 2a is an important pathogenetic event [12]. In HRS
cells, many different signaling molecules and pathways
such as Notch1, several receptor tyrosine kinases, the
PI3K and MEK/ERK pathways and the transcription fac-
tors NFκB, STAT and AP-1 are aberrantly activated [13].
These pathways are frequently driven by autocrine as
well as paracrine activation loops [14].
Vitamin D3 is a lipophilic molecule that belongs to the
family of steroid hormones. Its endocrine functions in
regulation of the calcium and phosphate utilization inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this endocrine character, newer studies added further
functions for vitamin D3 especially in the pathogenesis
of cancer. It has been shown that vitamin D3 is capable
to modulate proliferation, differentiation, metastasis, in-
vasion, angiogenesis and apoptosis via autocrine and
paracrine mechanisms [15-18].
Vitamin D3 effects are mainly mediated by its receptor,
the vitamin D receptor (VDR) to whom it binds in a
high-affinity. Ligand binding is associated with conform-
ational changes of the protein, allowing the interaction
with dimerization partners and subsequent nuclear im-
port [19]. VDR is a member of the superfamily of nu-
clear receptors for steroid hormones and acts as a
heterodimer by binding to vitamin D responsive ele-
ments as a ligand inducible transcription factor [20]. Nu-
clear localization saves the active receptor complex from
proteasomic degradation [19]. VDR expression can be
induced by vitamin D3 [21-23].
VDR is detectable by immunohistochemistry in den-
dritic cells [24]. In proliferating T-cells, VDR expression
was shown to be high and correlating with the prolifera-
tive status, whereas VDR expression in B-cells is low in
general [25,26]. Dendritic cells with tolerogenic proper-
ties can be induced by VDR [27,28].
Immunohistochemical studies revealed that VDR ex-
pression was detectable in most analyzed B-cell Non
Hodgkin Lymphoma (B-NHL) cases; however expression
was at very low levels compared with normal breast tis-
sue as well as with breast carcinoma in which VDR has
been shown to be of importance [29,30]. In diffuse large
B-Cell lymphoma derived cell lines, treatment with vita-
min D3 and a selective VDR-agonist reduced cell growth
whereas again observed VDR expression was low [29].
In the present study, we investigated the expression of
vitamin D receptor in a panel of HL and B-NHL in an
immunohistochemical approach in order to identify a
potential diagnostic marker and possible new therapeuti-
cal target for B-cell derived lymphomas.
Methods
Tissue samples
Tissue samples were retrieved from the files of the De-
partment of Pathology of the University of Frankfurt and
were originally submitted for diagnostic purposes. Cases
were analyzed after approval was obtained from the Uni-
versity of Frankfurt School of Medicine Institutional Re-
view Board for these studies. The study was performed
according to the updated Helsinki declaration and
informed consent was obtained from all patients.
Antibodies
Primary antibodies were obtained from Santa Cruz (VDR,
#sc13133, Santa Cruz, Heidelberg, Germany) and fromSigma (ß-Actin, Sigma, Deisenhofen, Germany). Second-
ary antibodies were purchased from Dako (Hamburg,
Germany).
Western blot analysis
Tissue lysates were prepared as described [31]. Proteins
were separated by electrophoresis on 12,5% polyacryl-
amide gels containing 0,1% sodium dodecyl sulfate and
were transferred to polyvinylidene difluoride membranes
(Bio Rad, Munich, Germany) using tank blotting tech-
nique. Membranes were blocked with phosphate-buf-
fered saline (PBS) containing 5% dry milk powder and
0,05% Tween20. Primary antibodies were used at dilu-
tions of 1/5000 (for VDR) and 1:10000 (for ß-Actin) in
PBS with 5% milk powder, and bound antibody was
detected with the appropriate secondary HRP-coupled
antibodies (Dako) in 5% milk supplemented with 0,05%
Tween20 for 60 min. Signals were detected by using the
ECL plus system (GE Healthcare, Munich, Germany),
High Performance ECL chemiluminescence films (GE
Healthcare) and Readymatic developer and fixer (Care-
stream Health Inc., NY, USA).
Immunohistochemistry
Immunohistochemistry was performed with 5 μm sections
of tissue of complete lymph node biopsies fixed in 5% buf-
fered formalin embedded in paraffin. After dewaxing with
xylene, antigen was retrieved by boiling the sections for 10
minutes in a microwave oven in 10 mM Na citrate at pH
6.0. Subsequently sections were blocked with BSA (5% in
Tris buffered saline (TBS, Sigma). Sections were incubated
for 12 hours with the primary antibody in at 4°C in TBS.
Secondary, enzyme coupled mouse Ig-specific antibody
(Dako) was incubated for 1 hour at room temperature.
Staining was visualized with a catalyzed signal amplification
Kit (K1500; Dako). For picture acquisition, an Olympus
BX-51 microscope (Olympus, Hamburg, Germany)
equipped with UPlanFL and PlanApo objective lenses (10x/
0,3, 20x/0,5, and 40x/0,65) was used. Fotographs were pro-
cessed with Adobe Photoshop 7.0 (Adobe, San Jose, CA).
Reactions lacking primary antibody did not show any
noteworthy non specific background.
Statistical analysis
Data analysis was performed using the GraphPad Prism
3.0 software (GraphPad, San Diego, CA). P-value in group
comparison was determined using the two-sided Fisher's
exact test. The criterion of significance was p< 0.05.
Results and discussion
VDR can be detected in formalin fixed tissue by
immunohistochemistry
Like most cell types which are responsive to vitamin D3,
also T-lymphocytes express constitutively VDR [32]. B-
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up regulated by specific stimuli [33-35]. Using RT-PCR,
VDR expression could be demonstrated in naïve, germi-
nal center and memory B-cells at low levels [36]. VDR
expression in non activated B-cells in tonsils could only
be detected after induction by vitamin D3 and interleu-
kin 4 [25,36,37].
Using immunohistochemistry (IHC), VDR levels in B-
cells in reactive lymph nodes or in hyperplastic tonsils
were below detection limits (data not shown), while den-
dritic cells (DC), in line with previous data [24], stained
positive as serving as an internal positive control (data
not shown). High expression of VDR in DC served as a
further control for the applied IHC method. To validate
the IHC staining of VDR, Western blot analyses of B-
NHL cases with high and low DC-content as obtained
by IHC were performed using the corresponding frozen
tissues. Signals for VDR were obtained at the expected
molecular weight at around 48 kDa which appeared
stronger in a DC-rich case of follicular lymphoma (FL).
compared to a weaker signal in a FL-case with a low
DC-count. (Figure 1)
VDR is highly expressed in most HL cases but only in few
B-NHL cases
Effects of sunlight, especially ultraviolet radiation regard-
ing the risk of development of lymphoma, are discussedFigure 1 Controls for the immunohistochemical staining of
VDR. (a) Immunohistochemical staining of VDR of two cases of B-
NHL, both follicular lymphoma subtype: one case appearing rich in
DC displays strong VDR positivity (case a) compared to another
showing only few VDR positive DC (case b). (b) Frozen material of
these cases was lysed and analyzed for VDR content by western
blotting. In line with the immunohistochemical staining results, high
VDR amount was detected in the DC rich case (case a), while a faint
band was detected in the DC poor case (case b).contradictorily [38-41]. Expression of VDR in B-cell
lymphoma derived cell lines has been shown immuno-
histochemically long ago. However, expression levels of
VDR in HL are still unknown [29].
We used immunhistochemistry to analyze a panel of
B-cell lymphomas being composed of a total of 193
cases, namely 55 cases of HL (26 NSHL, 20 MCHL, 9
NLPHL), 138 cases of B-NHL (38 follicular lymphomas,
59 diffuse large B cell lymphomas, 10 mantle cell lymph-
omas, 5 marginal zone lymphomas, 6 Burkitt lymph-
omas, 10 primary mediastinal B cell lymphomas, 10 B
cell chronic lymphocytic leukemias). A case was rated
positive when more than 50% of the tumor cells dis-
played VDR-immunoreaction. This threshold was set in
order to avoid underestimation of VDR expression in
lymphoma cases with inhomogeneous staining due to
possible fixation artifacts of the tissue. As seen before,
DC also showed positivity in lymphoma cases and there-
fore served as an internal positive control.
VDR-positivity of tumor cells was observed in 80%
(44/55) of HL cases but only in 17.4% (24/138) of total
B-NHL entities tested (Figures 2 and 3). Using Fisher’s
exact test on contingency tables, statistical analysis of
VDR-positive cases revealed statistical significance be-
tween the group of HL and B-NHL (p< 0.0001).
Among the group of HL, the highest number of posi-
tive cases was found in NSHL with 88.5% (23/26) of
cases, followed by MCHL with 75% (15/20) and NLPHL
in 67.7% (6/9) of positive cases. The number of positive
cases in B-NHL was clearly lower at 17.4% of cases (24/
138). Of these, most positive cases were among DLBCL
at 22% (13/59), FL at 15.8% (6/38) and BL 33.3% (2/6).
(Figure 3b) However, only 6 BL could be analyzed so the
number of positive cases might be different in a larger
cohort. In the vast majority of HL B-NHL cases, HRS
cells of HL and LP cells of NLPHL showed a cytoplas-
mic and also nuclear immunoreaction, whereas VDR
was mainly detectable in the cytoplasm of the tumor
cells B-NHL cases. Further, VDR staining intensity in
tumor cells of HL was much stronger in general when
compared to positive B-NHL cases. (Figure 2)
The strong VDR expression and nuclear localization in
cHL as well as in NLPHL seems somehow unexpected
as these lymphomas have different cellular origins and
different marker profiles have been proven [1]. In a glo-
bal gene expression analysis comparing NLPHL with
other lymphoma types it was shown that NLPHL is des-
pite the known differences very closely related to cHL.
As cHL NLPHL is also characterized by a loss of marker
molecules of B-cells. Both lymphoma entities show a
strong constitutive NF-kB activity. Taken together it was
shown that their global gene expression profiles differ
only in few genes [42]. To go back to histological find-
ings cHL and NLPHL both show a similar mixed cellular
Figure 2 Immunohistochemical detection of VDR in HL. Exemplary cases of HL and B-NHL with expression of VDR are shown at low (10x)
and high (40x, insert) magnification. The HL entities nodular sclerosing subtype (a), mixed cellularity subtype (b) and nodular lymphocyte
predominant Hodgkin Lymphoma (c) are shown. Of B-NHL, samples of diffuse large B-cell lymphoma (d), follicular lymphoma (e), B-cell chronic
lymphatic leukemia (f), marginal zone lymphoma (g) and Burkitt´s lymphoma (h) cases with staining reactions scored as positive are shown. In
nodular sclerosing subtype of HL (A), also staining of activated T-cells and macrophages can be seen in the non neoplastic cellular background.
Also in follicular lymphoma (E) macrophages staining strongly positive can be seen besides the tumor cells. B-NHL showed mostly cytoplasmatic
positivity. Nuclear staining was found only in few cells of rare cases.
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most likely provide the tumor cells of both entities with
an analog pattern of paracrine stimuli.Upon interaction with vitamin D3, retinoid-X-recep-
tors are recruited to VDR, forming a receptor complex
as heterodimerization partners. This complex migrates
Figure 3 Immunohistochemical detection of VDR in B-cell lymphoma. 80% of HL showed strong nuclear positivity for VDR while positivity of
B-NHL was only seen in 17.4% of cases (a). Among HL subtypes, VDR shows strongest positivity in classical subtypes NSHL (88.5%), followed by
MCHL (75%). DLBCL with 22% and FL with 15.8% of positive cases are B-NHL subtypes with most prominent VDR reactivity. 33.3% of BL showed
positivity for VDR, however only 6 cases have been analyzed (b).
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and activates transcription of dependent genes. Only few
cell types have been described to show nuclear VDR
without previous ligand induced activation [19,43].
Staining reactions for VDR in HL show mainly nuclear
signals. Therefore it seems most likely that also in HRS
cells VDR is ligand bound and activated, and thus de-
tectable in the nucleus. (Figure 2a-c) Vitamin D3 acti-
vation by sunlight could not be taken as a definite ligand
source, since influence of ultraviolet radiation has not
been proven to have an influence on lymphoma risk
[44]. Thus, activation of VDR raises the question of a
possible endogenous source of ligand in tumor tissue.
Given the typically low, subnanomolar plasma concen-
tration of vitamin D3, availability of hormone in a suit-
able, effective concentration requires the presence of an
exogenous cell source. Macrophages and monocytes on
the one hand have been shown to express vitamin D3
and also been identified to express 1α-hydroxylase, the
enzyme that is responsible activating vitamin D3 into its
metabolic active form [45,46]. As these cell types are
part the non neoplastic cellular infiltrate of HL, they
might be a possible source of ligands acting in a para-
crine manner.
About 40% of HL cases, mainly of MC subtype are
infected with Epstein-Barr Virus (EBV) [1]. A recent
study has shown that the EBV encoded protein EBNA3
is a possible binding partner of VDR, and that EBNA3 -
VDR interaction blocks activation of VDR dependent
gene expression, which protects EBV immortalized
lymphoblast cell lines from vitamin D3 induced growth
arrest and apoptosis [47]. As EBNA3 has not been
detected in HRS cells, a relevant interaction of VDR
with EBNA3 seems unlikely at least in HRS cells [12].
However, the interaction of EBNA3 with VDR in tumor
cell progenitors of HL might be advantageous in earlier
lymphoma development.The VDR gene is located on chromosome 12q12-q14.
Several single nucleotide polymorphisms of VDR, having
possible influences on cancer pathogenesis, have been
detected. Exemplarily, polymorphism rs2228570 results
in a VDR variant which is three amino acids longer than
its wild type and shows a lowered activity compared to
the wild type [48]. Polymorphisms rs1544410 and
rs731236 do not change VDR protein, but result in
enhanced stability of VDR messenger RNA [49,50]. As-
sociation to DLBCL, and increased risk for FL upon ex-
posure to ultraviolet radiation was reported for rs731236
[51,52]. As tumor cells in HL are very rare, micro dissec-
tion experiments would raise a possibility to elucidate
genomic vdr mutation status in HL.
Conclusions
In summary, this is the first study to report the strong
expression of VDR in the vast majority of HL cases,
while only low or none VDR expression was detected in
normal, non neoplastic B-cells and all analyzed B-NHL.
Nuclear localization of VDR suggests the active form of
detected VDR in HL. As VDR activity seems to be of im-
portance in B-NHL, VDR function in HL remains to be
elucidated.
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